Skip to content
Peregrine
  • Home
  • About Us
    • Company Overview
    • Our Mission
  • Our Funds
  • Portfolio
  • Team
  • ESG & Impact
  • News
  • Contact
  • Home
  • About Us
    • Company Overview
    • Our Mission
  • Our Funds
  • Portfolio
  • Team
  • ESG & Impact
  • News
  • Contact

News

Merck logo, clinical trial collaboration with Nectin Therapeutics

Nectin Therapeutics announced a mutual clinical trial with Merck

Read More
Pfizer logo, $25 million investment in Ribon Therapeutics

Ribon Therapeutics announced a $25M investment from Pfizer

Read More
Interventional Neuroradiology journal cover featuring EndoStream Medical’s Nautilus device illustration

EndoStream Medical’s Nautilus device for treating patients with brain aneurysm is featured on the cover of the acclaimed INR

Read More
Peregrine Ventures and Incentive Incubator logos, new investor consortium with Bristol Myers Squibb, Becton Dickinson and Elbit System

Peregrine Ventures Announces New Investor Consortium Including Bristol Myers Squibb, Becton Dickinson and Company, and Elbit Systems

Read More
Restore Medical founders, €2.5 million strategic investment from the European Innovation Council

Restore Medical secured a strategic investment of €2.5M from the European Innovation Council

Read More
Momentis Surgical team member working with the Hominis Surgical System, first patient cases

Memic announces completion of first patient cases using Hominis® Surgical System

Read More
Cordio Medical team, $18 million Series C funding round

Cordio Mecidal has completed a successful strategic Series C funding round raising a total of $18M

Read More
Magneto Thrombectomy Solutions team working in the laboratory, following successful First-in-Human procedure

Magneto Thrombectomy Solutions announces a successful First-in-Human

Read More
Cordio Mecidal

Ribon Therapeutics to present at the 2022 American Association for Cancer Research annual meeting

Read More
Nir Altschuler, CEO of CartiHeal, following the company’s acquisition by Bioventus

CartiHeal is acquired by Bioventus

Read More
Page1 Page2 Page3 Page4 Page5
  • Homepage
  • About Us
  • Our Funds
  • Portfolio
  • Team
  • ESG AND IMPACT
  • News
  • Contact
  • Homepage
  • About Us
  • Our Funds
  • Portfolio
  • Team
  • ESG AND IMPACT
  • News
  • Contact
Linkedin-in
  • Terms of Use
  • Privacy Policy
  • Accessibility Statment
  • Cookie Policy
  • Terms of Use
  • Privacy Policy
  • Accessibility Statment
  • Cookie Policy
©All rights reserved to Peregrine 2026

site by: 

razgroup-logo
Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
View preferences
  • {title}
  • {title}
  • {title}